BIOREGENX, INC. Files 2023 Annual Report on Form 10-K

TL;DR

<b>BIOREGENX, INC. has filed its 2023 annual report (10-K) detailing its financial performance and business operations.</b>

AI Summary

BIOREGENX, INC. (BRGX) filed a Annual Report (10-K) with the SEC on April 12, 2024. BIOREGENX, INC. filed its annual report for the fiscal year ending December 31, 2023. The company was formerly known as FINDIT, INC. and ARTEMIS ENERGY HOLDINGS, INC. Its business address is located at 7407 ZIEGLER ROAD, CHATTANOOGA, TN 37421. The company's SIC code is 7370, indicating services in computer programming and data processing. The filing was made on April 12, 2024.

Why It Matters

For investors and stakeholders tracking BIOREGENX, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of BIOREGENX, INC.'s financial health, operational status, and strategic direction for the fiscal year 2023. Understanding the company's historical performance and current standing is crucial for investors and stakeholders to assess future potential and risks.

Risk Assessment

Risk Level: low — BIOREGENX, INC. shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate, significant new financial data or strategic shifts that would inherently increase risk.

Analyst Insight

Review the full 10-K filing for detailed financial statements, risk factors, and management discussion to form an informed investment opinion.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reported period)
• 2024-04-12 — Filing Date (Date of submission)
• 7370 — SIC Code (Industry classification)

Key Players & Entities

• BIOREGENX, INC. (company) — Filer name
• FINDIT, INC. (company) — Former company name
• ARTEMIS ENERGY HOLDINGS, INC. (company) — Former company name
• CHATTANOOGA, TN (location) — Business address city and state
• 7407 ZIEGLER ROAD (address) — Business street address
• 2023-12-31 (date) — Fiscal year end
• 2024-04-12 (date) — Filing date

FAQ

Industry Context

BIOREGENX, INC. operates within the services sector, specifically computer programming and data processing, as indicated by its SIC code 7370.

Regulatory Implications

The filing adheres to the requirements of the Securities Exchange Act of 1934, as evidenced by the Form 10-K submission.

What Investors Should Do

1. Thoroughly review the financial statements and management's discussion and analysis within the 10-K.
2. Investigate the company's historical performance and any disclosed strategic initiatives.
3. Assess the risk factors section for potential challenges and uncertainties.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-04-12: Filing Date — Date the 10-K report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial 10-K filing for BIOREGENX, INC. under its current name, providing a baseline for future comparisons.

Key Financial Figures

• $0.001 — Section 12(g) of the Act: Common Stock, $0.001 par value Indicate by check mark if t
• $200,000 — s, DocSun will receive a signing fee of $200,000 (payable over ten months) and will rece
• $10 — revenue generated including 40% of the $10 per vehicle license fee from the EV aut
• $3.50 — . DocSun shall receive a license fee of $3.50 per subscriber. The first demo scan is
• $155,000 — e License Agreement, NuLife paid DocSun $155,000 for the development costs related to th
• $22,000 — ycoCheck system packages priced between $22,000 to $32,000, generating monthly recurrin
• $32,000 — stem packages priced between $22,000 to $32,000, generating monthly recurring revenue b
• $9.95 — The purchase price for one is currently $9.95. The price has varied over several year
• $19.00 — A promoted post is currently offered at $19.00 per promoted post. A post that is promo
• $4 — he global health market, valued at over $4 trillion, undergoes transformative shif
• $176 billion — ealth services, valued at approximately $176 billion. Preventive Healthcare: Increasing aw

Filing Documents

• bioregenx_i10k-123123.htm (10-K) — 555KB
• bioregenx_ex3100.htm (EX-31) — 14KB
• bioregenx_ex3200.htm (EX-32) — 5KB
• 0001683168-24-002317.txt (&nbsp;) — 2504KB
• fdit-20231231.xsd (EX-101.SCH) — 19KB
• fdit-20231231_cal.xml (EX-101.CAL) — 33KB
• fdit-20231231_def.xml (EX-101.DEF) — 59KB
• fdit-20231231_lab.xml (EX-101.LAB) — 201KB
• fdit-20231231_pre.xml (EX-101.PRE) — 161KB
• bioregenx_i10k-123123_htm.xml (XML) — 167KB

Risk Factors

Item 1A. Risk Factors 10

Unresolved staff comments

Item 1B. Unresolved staff comments 10

Properties

Item 2. Properties 10

Legal Proceedings

Item 3. Legal Proceedings 10

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 10 Part II

Market for Company's Common Equity, Related Stockholders Matters and Issuer Purchases of Equity Securities

Item 5. Market for Company's Common Equity, Related Stockholders Matters and Issuer Purchases of Equity Securities 11

Selected Financial Data

Item 6. Selected Financial Data 12

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 12

Quantitative and Qualitative Disclosures about Market Risk

Item 7A. Quantitative and Qualitative Disclosures about Market Risk 14

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 15

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 27

Controls and Procedures

Item 9A. Controls and Procedures 27

Other Information

Item 9B. Other Information 28 Part III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 29

Executive Compensation

Item 11. Executive Compensation 33

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 34

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 37

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 37 Part IV

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules 38

Signatures

Signatures 39 i PART I

BUSINESS

ITEM 1. BUSINESS BioRegenx, Inc. (formerly Findit, Inc.) was originally incorporated on December 23, 1998 in the state of Nevada. Effective March 8, 2024, BioRegenx, Inc., a Nevada corporation was merged into Findit, Inc. resulting in a change of control. Pursuant to the terms of the merger, the name of the company was changed to BioRegenx, Inc. (the "Company"). Pursuant to the merger, all of the issued and outstanding BioRegenx, Inc. common and preferred shares were exchanged for 851,977,296 common shares and 3,800 Series A preferred shares of the Company which represented 90.0% of the voting securities of the Company. Concurrently, holder(s) of the Company's Series A and Series B preferred shares retired all of their Series A and Series B preferred shares back into the treasury. The retired Series A and Series B preferred shares represented a voting control of 98.47% of the Company. Simultaneously, the majority shareholders retired a total of 172,197,602 common shares. The exchange value of the Company's stock was the average closing price of the Company for the month of November 2022. As soon as practical after the merger, both parties agreed to the implementation of up to a 1 for 25 reverse split of the Company's common and preferred stock to improve the Company's ability to attract institutional investors and analysts as well as to graduate to a senior exchange (OTCQB, NASDAQ). Operating Subsidiaries DocSun BioMedical Holdings, Inc. On January 11, 2024, pursuant to a Securities Exchange Agreement effective November 15, 2023 and an Addendum to the Securities Exchange Agreement dated December 5, 2023, BioRegenx acquired DocSun Biomedical Holdings, Inc. Pursuant to the Securities Exchange Agreement, BioRegenx acquired all of the issued and outstanding securities of DocSun in exchange for 4,800,000 BioRegenx common shares. Technology DocSun combines three proven technologies in the DocSun Artificial Intelligence (AI) Engine. The DocSun AI Engine integra

View Full Filing

View this 10-K filing on SEC EDGAR